Advanced Renal Cell Carcinoma Pipeline Insight| Companies- Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, and Others

May 25
16:00 2023
Advanced Renal Cell Carcinoma Pipeline Insight| Companies- Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, and Others

DelveInsight’s, “Advanced Renal Cell Carcinoma Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in the Advanced Renal Cell Carcinoma pipeline landscape. It covers the Advanced Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Advanced Renal Cell Carcinoma Pipeline treatment landscape of the report, click here @ Advanced Renal Cell Carcinoma Pipeline Outlook

 

Key Takeaways from the Advanced Renal Cell Carcinoma Pipeline Report

  • DelveInsight’s Advanced Renal Cell Carcinoma Pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Advanced Renal Cell Carcinoma.
  • The leading Advanced Renal Cell Carcinoma Companies include  Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others
  • Promising Advanced Renal Cell Carcinoma Pipeline Therapies include tivozanib (AV-951), Sorafenib, Tivozanib, Interferon Alfa, CCI-779, Atezolizumab (MPDL3280A), Bevacizumab, Sunitinib, Temsirolimus, Nexavar, IFN-alpha, and others
  • Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient’s own immune system to fight cancer. Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural killer (NK) cell populations in the body which fight cancer, which are known as endogenous tumor-infiltrating lymphocytes (TILs).

 

For further information, refer to the detailed Advanced Renal Cell Carcinoma Unmet Needs, Advanced Renal Cell Carcinoma Market Drivers, and Advanced Renal Cell Carcinoma Market Barriers, click here for Advanced Renal Cell Carcinoma Ongoing Clinical Trial Analysis

 

Advanced Renal Cell Carcinoma Overview

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. This type of cancer develops in the lining of very small tubes, or tubules, inside the kidney. These tubules help to remove waste products from the blood. Stage 4 RCC is the most advanced stage where the disease has spread from the kidneys to one or more distant areas of the body. According to a 2016 study Trusted Source, the outlook for advanced RCC depends largely on where the new tumors are growing in the body. For example, people with RCC that has spread to the pancreas have a higher overall survival rate than those where cancer has spread to the brain, bones, or liver.

 

Request a sample and discover the recent advances in Advanced Renal Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Renal Cell Carcinoma Treatment Landscape

 

Advanced Renal Cell Carcinoma Emerging Drugs

 

Belzutifan: Merck Sharp & Dohme

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a). Belzutifan binds to HIF-2a, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2a-HIF-1ß interaction, leading to reduced transcription and expression of HIF-2a target genes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of advanced renal cell carcinoma.

 

IPI-549: Infinity Pharmaceuticals

Eganelisib is a first-in-class, oral, once-daily, immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Selective PI3K-gamma inhibition represents a unique and potentially transformative approach within immuno-oncology (I/O), and IPI-549 has the potential to be a first-in-class therapy. Preclinical research conducted by Infinity and academic collaborators demonstrates that IPI-549 works by reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of advanced renal cell carcinoma.

 

JANX008: Janux Therapeutics

JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of advanced renal cell carcinoma.

 

Dive deep into rich insights for drugs for Advanced Renal Cell Carcinoma Market Drivers and Advanced Renal Cell Carcinoma Market Barriers, click here @ Advanced Renal Cell Carcinoma Unmet Needs and Analyst Views

 

Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme.

 

Scope of the Advanced Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Renal Cell Carcinoma Companies- Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others
  • Advanced Renal Cell Carcinoma Pipeline Therapies- tivozanib (AV-951), Sorafenib, Tivozanib, Interferon Alfa, CCI-779, Atezolizumab (MPDL3280A), Bevacizumab, Sunitinib, Temsirolimus, Nexavar, IFN-alpha, and others
  • Advanced Renal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Advanced Renal Cell Carcinoma Mergers and acquisitions, Advanced Renal Cell Carcinoma Licensing Activities @ Advanced Renal Cell Carcinoma Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Belzutifan: Merck Sharp & Dohme
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IPI-549: Infinity Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. JANX008: Janux Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Renal Cell Carcinoma Key Companies
  21. Advanced Renal Cell Carcinoma Key Products
  22. Advanced Renal Cell Carcinoma- Unmet Needs
  23. Advanced Renal Cell Carcinoma- Market Drivers and Barriers
  24. Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
  25. Advanced Renal Cell Carcinoma Analyst Views
  26. Advanced Renal Cell Carcinoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories